Exploratory trials in mental health: Anything to learn from other disciplines?

Evidence-Based Mental Health

Volumn 20, Issue 1, 2017, Pages 21-24

  Trelle, Sven ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); HUMAN; MENTAL DISEASE; METHODOLOGY; PILOT STUDY;

CLINICAL TRIALS AS TOPIC; HUMANS; MENTAL DISORDERS; PILOT PROJECTS; RESEARCH DESIGN;

EID: 85010310679     PISSN: 13620347     EISSN: None     Source Type: Journal    
DOI: 10.1136/eb-2016-102581     Document Type: Article

References (39)

1. Hernan MA, Robins JM. Causal inference. Cambridge, MA, 2015. https://http://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/ (accessed 25 Jul 2016).
2. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: general considerations for clinical trials E8. London, UK: International Conference on Harmonisation, 1997.
3. Palesch YY, Tilley BC, Sackett DL, et al. Applying a phase II futility study design to therapeutic stroke trials. Stroke 2005;36:2410–14.
4. Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 2015;313:1619–20.
5. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014;6:37.
6. Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord 2015;17:63–75.
7. Patel MX, Collins S, Hellier J, et al. The quality of reporting of phase II and III trials for new antipsychotics: a systematic review. Psychol Med 2015;45:467–79.
8. Sharma MR, Stadler WM, Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst 2011;103:1093–100.
9. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1–10.
10. Schumi J, Wittes JT. Through the looking glass: understanding non-inferiority. Trials 2011;12:106.
11. Ensign LG, Gehan EA, Kamen DS, et al. An optimal three-stage design for phase II clinical trials. Stat Med 1994;13:1727–36.
12. Chen TT. Optimal three-stage designs for phase II cancer clinical trials. Stat Med 1997;16:2701–11.
13. Chen S, Soong SJ, Wheeler RH. An efficient multiple-stage procedure for phase II clinical trials that have high response rate objectives. Control Clin Trials 1994;15:277–83.
14. Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 1995;51:1372–83.
15. Wason JM, Mander AP, Eisen TG. Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points. Eur J Cancer 2011;47:983–9.
16. Wason JM, Mander AP, Thompson SG. Optimal multistage designs for randomised clinical trials with continuous outcomes. Stat Med 2012;31:301–12.
17. Mander AP, Thompson SG. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. Contemp Clin Trials 2010;31:572–8.
18. Potkin SG, Kimura T, Guarino J. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Ther Adv Psychopharmacol 2015;5:322–31.
19. Mandrekar SJ, Sargent DJ. Randomized phase II trials: time for a new era in clinical trial design. J Thorac Oncol 2010;5:932–4.
20. Lachin JM. A review of methods for futility stopping based on conditional power. Stat Med 2005;24:2747–64.
21. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375–81.
22. Wieand HS. Randomized phase II trials: what does randomization gain? J Clin Oncol 2005;23:1794–5.
23. Jung SH, George SL. Between-arm comparisons in randomized phase II trials. J Biopharm Stat 2009;19:456–68.
24. Liu PY, LeBlanc M, Desai M. False positive rates of randomized phase II designs. Control Clin Trials 1999;20:343–52.
25. Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005;23:7199–206.
26. Jarskog LF, Lowy MT, Grove RA, et al. A phase II study of a histamine H(3) receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophr Res 2015;164:136–42.
27. Wason J, Magirr D, Law M, et al. Some recommendations for multi-arm multi-stage trials. Stat Methods Med Res 2016;25:716–27.
28. Chow SC, Chang M. Adaptive design methods in clinical trials—a review. Orphanet J Rare Dis 2008;3:11.
29. Wason JM, Trippa L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med 2014;33:2206–21.
30. Wason JM, Jaki T. A review of statistical designs for improving the efficiency of phase II studies in oncology. Stat Methods Med Res 2016;25:1010–21.
31. Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med 2016;375:11–22.
32. Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 2016;375:23–34.
33. Bateman RJ, Benzinger TL, Berry S, et al. The DIAN-TU Next Generation Alzheimer’s prevention trial: adaptive design and disease progression model. Alzheimers Dement 2017;13:8–19.
34. Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ 2016;355:i5239.
35. Eldridge SM, Lancaster GA, Campbell MJ, et al. Defining feasibility and pilot studies in preparation for randomised controlled trials: development of a conceptual framework. PLoS ONE 2016;11:e0150205.
36. Arain M, Campbell MJ, Cooper CL, et al. What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol 2010;10:67.
37. Cook JA, Beard DJ, Cook JR, et al. The curious case of an internal pilot in a multicentre randomised trial—time for a rethink? Pilot Feasibility Stud 2016;2:73.
38. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol 2010;10:1.
39. Kasenda B, von Elm E, You J, et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA 2014;311:1045–51.